$30.45
+2.40 (+8.56%)
USD · as of 2026-07-29 · marketstack
stale — last close 2026-07-29, not a live quote
Clinical trials
catalyst calendar across sponsors →Studies where VYNE is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
32 interventional · 15 with posted results
Held by 5 tracked-famous managers (CITADEL ADVISORS LLC, TWO SIGMA INVESTMENTS, LP, SUSQUEHANNA INTERNATIONAL GROUP, LLP, JANE STREET GROUP, LLC, RENAISSANCE TECHNOLOGIES LLC) · FINRA short interest 1.0 days to cover (settled 2026-07-15) · government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Updated |
|---|---|---|---|---|---|---|---|
| A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of VYN201 Gel in Subjects With Non-segmental Vitiligo.NCT06493578To evaluate the efficacy of VYN201 compared to vehicle at Week 24 in subjects with NSV.Randomized · Quadruple-masked · Treatment | Phase 2 | Terminatedsponsor's stated reason: Business Decision | Drug: VYN201 Gel, Vehicle Gel | Non-segmental Vitiligo | 205 | 2025-07-10actual | 2026-04-21 |
| Safety, Pharmacokinetics and Efficacy of FMX114 Versus Vehicle in Adults With Atopic DermatitisNCT04927572Mean Change from Baseline in Atopic Dermatitis Severity Index (ADSI) score at Day 29Randomized · Double-masked · Treatment | Phase 1/2 | Completed | Drug: FMX114 · Other: Vehicle | Atopic Dermatitis | 21 | 2022-08-09actual | 2022-08-31 |
| Study of the Long Term Safety of Serlopitant for the Treatment of Pruritus (Itch)NCT03540160results2020-11-30Number of Subjects With Treatment-emergent Adverse EventsOpen-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Terminatedsponsor's stated reason: No longer pursuing development of serlopitant | Drug: 5 mg Serlopitant Tablets | Pruritus, Prurigo Nodularis, Atopic Dermatitis, Psoriasis | 558 | 2020-04-08actual | 2021-05-20 |
| A Study to Compare FCD105 Foam to Minocycline 3% Foam, Adapalene 0.3% Foam and Vehicle Foam.NCT04104685Absolute change from Baseline in inflammatory lesion counts at week 12Randomized · Double-masked · Treatment | Phase 2 | Completed | Combination product: FCD105 · Drug: 3% Minocycline Foam, 0.3% Adapalene Foam · Other: Vehicle Foam | Acne Vulgaris | 446 | 2020-02-28actual | 2021-02-05 |
| Study of the Efficacy, Safety and Tolerability of Serlopitant for the Treatment of Pruritus (Itch) With Prurigo NodularisNCT03546816results2020-09-07Percent of Subjects With Worst-Itch Numeric Rating Scale 4-point Responder at Week 10Randomized · Quadruple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Completed | Drug: 5mg Serlopitant Tablets, Placebo Tablets | Pruritus, Prurigo Nodularis | 285 | 2020-01-14actual | 2021-05-20 |
| Study of the Efficacy, Safety and Tolerability of Serlopitant for the Treatment of Pruritus (Itch) With Prurigo NodularisNCT03677401results2020-10-28Percent of Participants With Worst Itch Numeric Rating Scale (WI-NRS) 4-point Responder Rate at Week 10Randomized · Quadruple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Completed | Drug: 5mg Serlopitant Tablets, Placebo Tablets | Pruritus, Prurigo Nodularis | 295 | 2020-01-09actual | 2021-05-20 |
| Study of the Efficacy, Safety, and Tolerability of Serlopitant for the Treatment of Chronic Pruritus of Unknown OriginNCT03841331results2020-09-23Worst Itch Numeric Rating Scale 4-point Responder Rate at Week 10Randomized · Quadruple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Completed | Drug: 5 mg Serlopitant Tablets, Matching Placebo Tablets | Pruritus | 233 | 2019-12-10actual | 2021-05-20 |
| A Study Comparing Two Topicals in the Treatment of Acne VulgarisNCT03743038results2021-02-23Number of Participants With 0 to 4 Investigator's Global Assessment Score at Week 6Randomized · Double-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 1 | Completed | Drug: FMX101 vehicle · Other: Hydro-alcohol solution | Acne Vulgaris | 12 | 2019-02-11actual | 2021-04-06 |
| A Study to Evaluate the Long-Term Safety of Topical Administration of FMX103 in the Treatment of Moderate to Severe Papulopustular RosaceaNCT03276936results2020-12-29Absolute Change From Baseline in Inflammatory Lesion Count at Week 40Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Completed | Drug: FMX103 1.5% | Papulopustular Rosacea | 504 | 2019-01-03actual | 2022-01-18 |
| Study of the Efficacy, Safety and Tolerability of Serlopitant for the Treatment of Pruritus (Itch) With Plaque PsoriasisNCT03343639results2019-06-12WI-NRS 4-point Responder Rate at Week 8Randomized · Quadruple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Completed | Drug: 5 mg Serlopitant Tablets, Matching Placebo Tablets | Pruritus, Psoriasis | 204 | 2018-10-23actual | 2021-05-20 |
| A Study to Evaluate the Efficacy and Safety of Topical Administration of FMX101 in the Treatment of Moderate-to-Severe Acne VulgarisNCT03271021results2020-02-21The Absolute Change From Baseline in the Inflammatory Lesion Count at Week 12.Randomized · Quadruple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Completed | Drug: FMX101, Vehicle Foam | Acne Vulgaris | 1,488 | 2018-09-04actual | 2022-01-18 |
| A Study (Study 1) to Evaluate the Safety and Efficacy of FMX103 1.5% Topical Minocycline Foam in the Treatment of Facial Papulopustular RosaceaNCT03142451results2020-12-17The Absolute Change From Day 0/Baseline in the Inflammatory Lesion Count at Week 12Randomized · Double-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Completed | Drug: FMX103 minocycline foam 1.5%, Vehicle foam | Facial Papulopustular Rosacea | 751 | 2018-08-31actual | 2021-01-29 |
| Study of the Efficacy, Safety, and Tolerability of Serlopitant for the Treatment of Refractory Chronic CoughNCT03282591results2019-10-22Change in 24-hour Objective Cough Frequency (Log Normalized Percent Change Relative to Placebo)Randomized · Quadruple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Completed | Drug: 5 mg Serlopitant Tablets, Matching Placebo Tablets | Refractory Chronic Cough | 185 | 2018-08-15actual | 2021-05-20 |
| A Study (Study 2) to Evaluate the Safety and Efficacy of FMX103 1.5% Topical Minocycline Foam in the Treatment of Facial Papulopustular RosaceaNCT04608500results2020-12-16The Absolute Change From Day 0/Baseline in the Inflammatory Lesion Count at Week 12Randomized · Double-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Completed | Drug: FMX103 minocycline foam 1.5%, Vehicle foam | Facial Papulopustular Rosacea | 771 | 2018-07-02actual | 2021-01-07 |
| Study of the Efficacy, Safety, and Tolerability of Serlopitant for Pruritus (Itch) in Atopic DermatitisNCT02975206results2019-03-05Change in WI-NRS From Baseline to Week 6Randomized · Quadruple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Completed | Drug: Serlopitant High Dose, Placebo Oral Tablet, Serlopitant Low Dose | Pruritus, Atopic Dermatitis | 484 | 2018-01-16actual | 2021-05-20 |
| A Study to Compare the Efficacy and Safety of Topical Administration of FMX-101 for Treatment of Moderate-to-Severe AcneNCT02815267results2020-09-22Absolute Change From Baseline in the Inflammatory Lesion Count at Week 12Randomized · Double-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Completed | Drug: FMX-101, 4% minocycline foam, Vehicle Foam | Acne Vulgaris | 466 | 2017-10-13actual | 2022-01-18 |
| A Study to Compare the Efficacy and Safety of Topical Administration of FMX-101 for Treatment of Moderate-to-Severe AcneNCT02815280results2020-11-24Absolute Change From Baseline in the Inflammatory Lesion Count at Week 12Randomized · Double-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Completed | Drug: FMX-101, 4% minocycline foam, Vehicle Foam | Acne Vulgaris | 495 | 2017-10-13actual | 2022-01-18 |
| Study of the Efficacy, Safety & Tolerability of Serlopitant for Pruritus (Itch) After Burn InjuryNCT02975271Change in Itch Intensity - Numeric Rating ScaleRandomized · Quadruple-masked · Treatment | Phase 2 | Terminatedsponsor's stated reason: Business Reasons | Drug: Serlopitant, Placebo | Pruritus, Burns | 1 | 2017-01-17actual | 2021-05-20 |
| A Randomized, Controlled Study to Evaluate the Sensitizing Potential of FMX-101 in Healthy Volunteers Using a Repeat Insult Patch Test DesignNCT04052711Assessment of recurrence of a cutaneous response at Rechallenge equivalent to or more severe than that observed at Challenge.Open-label · Other | Phase 1 | Completed | Drug: FMX-101 | Healthy | 233 | 2016-11-19actual | 2019-08-21 |
| Dermal Photo Allergic Skin ReactionNCT04070755Assessment of photoallergic skin reactions (numerical equivalent scoring of erythema and edema) after periodic exposure to IP on irradiated and non-irradiated skinOpen-label · Treatment | Phase 1 | Completed | Drug: FMX-101 | Healthy | 56 | 2016-11-18actual | 2019-08-28 |
| Dermal Cumulative Irritant Patch StudyNCT04064125Comparison of mean cumulative irritation over time for IP versus controls using a dermal irritation numerical equivalent grading tool.Open-label · Treatment | Phase 1 | Completed | Drug: FMX-101 | Healthy | 42 | 2016-09-28actual | 2019-08-28 |
| Dermal Phototoxicity StudyNCT04070742Comparison between Test and Vehicle sites of the post-irradiation erythema severity at 96 hours post-application using a dermal response numerical equivalent scoreOpen-label · Treatment | Phase 1 | Completed | Drug: FMX101 | Healthy | 32 | 2016-09-07actual | 2019-09-11 |
| Safety and Efficacy Study of a Topical Minocycline Foam in Patients With Papulopustular RosaceaNCT02601963the absolute change in inflammatory lesion count at Week 12 compared to Baseline.Randomized · Double-masked · Treatment | Phase 2 | Completed | Drug: FMX-103 1.5%, FMX-103 3%, Vehicle foam (0%) | Rosacea, Papulopustular Rosacea | 233 | Aug 2016actual | 2017-02-15 |
| A Randomized Placebo-Controlled Study of the Neurokinin-1 (NK1) Receptor Antagonist Serlopitant Prurigo Nodularis (PN)NCT02196324results2021-02-02Average Visual Analog Scale at BaselineRandomized · Quadruple-masked · Treatment | Phase 2 | Completed | Drug: serlopitant, Placebo | Prurigo Nodularis | 128 | 2016-05-27actual | 2021-05-20 |
| Safety, Tolerability and Efficacy Study of Doxycycline Foam for the Prevention of EGFRI Skin Toxicity in Cancer PatientsNCT02239731To investigate the safety and tolerability of FDX104 in cancer patients receiving EGFRIRandomized · Quadruple-masked · Prevention | Phase 2 | Completed | Drug: FDX104 (4% Doxycycline) | Rash Due to Epidermal Growth Factor Receptor Inhibitors | 24 | Oct 2015actual | 2018-02-27 |
| A Pharmacokinetic Study of Minocycline in Male and Female VolunteersNCT02250859adverse eventsOpen-label · Treatment | Phase 1 | Completed | Drug: FMX101, Minocycline 4% foam | Acne | 12 | Dec 2014actual | 2021-02-25 |
| VPD-737 for Treatment of Chronic PruritusNCT01951274Visual Analog ScaleRandomized · Quadruple-masked · Treatment | Phase 2 | Completed | Drug: VPD-737, Placebo | Chronic Pruritus | 257 | 2014-12-02actual | 2022-05-13 |
| Study to Evaluate the Safety and Efficacy of Topical Minocycline FXFM244 in Rosacea PatientsNCT01134991Improvement in signs and symptoms of rosaceaRandomized · Triple-masked · Treatment | Phase 2 | Terminatedsponsor's stated reason: Difficulty in recruitment | Drug: Topical Minocycline Foam FXFM244 | Rosacea | 21 | Mar 2014actual | 2015-08-26 |
| Clinical Study to Evaluate Tolerability and Safety of FXFM244 and to Monitor Clinical Effect in Acne Vulgaris PatientsNCT01362010Decrease in lesions countRandomized · Quadruple-masked · Treatment | Phase 2 | Completed | Drug: Topical Minocycline Foam FXFM244 | Acne Vulgaris | 150 | Jun 2013actual | 2013-08-15 |
| Study to Evaluate the Safety and Efficacy of Topical Minocycline FXFM244 in Impetigo PatientsNCT01171326Decrease in lesion countRandomized · Triple-masked · Treatment | Phase 2 | Completed | Drug: Topical Minocycline Foam FXFM244 | Impetigo | 32 | Mar 2012actual | 2013-12-10 |
| A Study of MK0594 in Patients With Alcohol Dependence (0594-020)NCT00835718no heavy alcohol drinking and safety as measured by adverse experiences, laboratory safety test, vital signs, ECG, and physical examinationRandomized · Double-masked · Treatment | Phase 2 | Terminated | Drug: Comparator: MK0594 5 mg/day, Comparator: MK0594 1 mg/day, Comparator: MK0594 1 mg/week, Comparator: Placebo to MK0594 | Alcohol Dependence | 162 | 2010-03-11actual | 2021-05-20 |
| Safety and Efficacy of MK0594 to Treat Overactive Bladder (0594-003)NCT00290563Change in baseline in average daily micturitions as recorded on patient voiding diaries.Randomized · Double-masked · Treatment | Phase 2 | Completed | Drug: MK0594 | Urinary Incontinence, Overactive Bladder | 557 | Aug 2007actual | 2021-05-19 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19